Fig. 8.

Concomitant treatment of ES2 plus dabrafenib results in apoptosis of melanoma cells. a, Images of melanoma sections from Tyr-BE transgenic mice. The tissue sections were stained for TUNEL+ cells (red) to measure apoptosis and DAPI (blue) for total nuclei. Quantification of the number of TUNEL+ cells in saline (n=4), Dabrafenib alone (n=4), ES2 alone (n=3), and ES2 + Dabrafenib (n=4) treatment. ES2 + Dab resulted in a 23-fold induction in apoptosis compared to saline, Dab alone or ES2 alone (p<0.001). There was no difference between saline, Dab alone or ES2 alone (p=0.99). ANOVA Scheffe PostHoc test. b, Concomitant treatment of ES2 plus dabrafenib improves overall survival. Kaplan-Meier curves for survival of mice under different treatments. CON – vehicle alone, ES2 – ES2 alone, DAB – Dabrafenib alone, ES2DAB – ES2 plus Dabrafenib. For 25,000 cells: CON – n=4, ES2 – n=4, DAB – n=4, ES2DAB – n=6. Log rank test of significance. For 750,000 cells: CON – n=6, ES2 – n=5, DAB – n=4, ES2DAB – n=4. c, Treatment regimen for aged mice. No statistically significant (N.S.) difference in change in White Blood Cells (WBC), Platelets (PLT), Red Blood Cells (RBC) or weight of mice between ES2 treatment and controls (n=5 per treatment). No statistically significant difference in endpoint plasma urea between ES2 treatment and controls (n=5 per treatment). d, Representative images of liver sections stained for SA-β-gal. Quantification of SA-β-gal+ cells in liver section shows reduced SA-β-gal+ cells after ES2 treatment (p=0.03) (n=5 per treatment). Student T-test. See also Fig. S6.